Get notified when MLYS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Security Interest In Substantially All Assets Including IP (new) — Lenders hold senior claim on core technology and operating assets; default could trigger foreclosure and liquidation of collateral, potentially ending operations.
  • Material Adverse Change to Lorundrostat Is Explicit Loan Default Trigger (new) — Any material adverse change or withdrawal event for the lead product candidate triggers acceleration of all debt obligations including make-whole premiums.
  • Company Does Not Expect to Generate Sufficient Cash Flow to Service Debt (new) — Management states business will not generate cash flow from operations to service debt in the foreseeable future; may require asset sales, debt restructuring, or dilutive equity raises.
NASDAQ: MLYS Mineralys Therapeutics, Inc. 10-Q

MLYS: net income -$241.1M. MLYS, draws debt as Dec 2026 FDA decision nears

Filed August 11, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 12, 2025 · ~2 min read

Key Changes

  • high

    Paid Tanabe upfront in June 2026 to eliminate all future royalty obligations (previously mid-single-digit to 10% of net sales) and convert the license to perpetual, royalty-free; expensed immediately as R&D, driving six-month operating loss to prior year.

    Legal Proceedings: Tanabe license amendment verify on EDGAR →
  • high

    Drew from new senior secured term loan (SOFR + 5.50%, 9.15% at inception); remaining tranches contingent on FDA approval by April 2027 and sales milestones. Loan secured by substantially all assets including IP; default triggers include material adverse change to lorundrostat.

    Notes: Senior secured term loan verify on EDGAR →
  • high

    NDA submitted December 2025, accepted by FDA with PDUFA target action date of December 22, 2026. Management states current cash position sufficient to fund operations including commercial launch at least twelve months.

    MD&A: NDA submission and PDUFA date verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.

Partner

Trade MLYS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 12, 2026 · How we verify